NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $13 | $17 | $20 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $14 | $14 | $27 | $75 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20 | $28 | $44 | $95 |
| Operating Income | -$20 | -$28 | -$44 | -$95 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5 | -$3 | $5 | $2 |
| Pre-Tax Income | -$25 | -$30 | -$40 | -$93 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$30 | -$40 | -$93 |
| % Margin | – | – | – | – |
| EPS | -2.39 | -3.98 | -0.6 | -7.44 |
| % Growth | 39.9% | -563.3% | 91.9% | – |
| EPS Diluted | -2.39 | -3.98 | -0.6 | -7.44 |
| Weighted Avg Shares Out | 11 | 8 | 66 | 47 |
| Weighted Avg Shares Out Dil | 11 | 8 | 66 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$24 | -$30 | -$40 | -$93 |
| % Margin | – | – | – | – |